Mar 29, 2026
Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.
Mar 26, 2026
A vaccine and two novel tuberculosis treatments are advancing through Phase III trials, marking renewed momentum in TB research. Tuberculosis claims over 1.25 million lives annually with 10.6 million new cases in 2023, while current treatments face challenges of high pill burden, toxicity, and rising resistance.
Mar 23, 2026
A study of nearly 70,000 children found girls exposed to SARS-CoV-2 infection in utero had a 44% increased risk of autism spectrum disorder. The research showed 3.97% of pregnant women had COVID-19 infection, with most cases occurring in the third trimester. No increased risk was observed for boys or for speech/language and motor delays overall.
Mar 20, 2026
The FDA announced major policy changes including requiring only one study for drug approvals instead of two, and offering performance bonuses to reviewers who complete work ahead of schedule while maintaining thoroughness.
Mar 14, 2026
Scientists have developed multiple breakthrough delivery systems for gene editing and mRNA therapies, including a simple amino acid supplement that increases delivery 20-fold and a CRISPR gene drive that reverses antibiotic resistance in bacterial populations.
Mar 13, 2026
Moderna's stock shows mixed signals with recent gains offset by multi-year declines. Valuation models suggest shares may be overvalued on some metrics while analysts maintain Hold ratings with downside price targets.
Mar 12, 2026
Arcturus Therapeutics completed three 28-day inhaled mRNA cohorts for cystic fibrosis that were well-tolerated and showed early biological signals. The company is preparing a 12-week Phase 2 study with tightened eligibility criteria and expanded enrollment into Europe and the Middle East.
Mar 12, 2026
Federal vaccine advisers have dropped a plan to reconsider mRNA COVID-19 vaccine recommendations amid Republican concerns about midterm election impacts. The committee maintains its September 2025 decision on shared clinical decision-making.
Mar 12, 2026
New research from 18 countries shows COVID-19 vaccination during pregnancy, particularly with booster doses, significantly reduces the risk of preeclampsia and other serious complications for both mothers and babies.
Mar 11, 2026
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Mar 10, 2026
Allergic rhinitis demonstrates both protective and risk associations with COVID-19 symptoms, while sublingual immunotherapy modifies respiratory and fever outcomes in patients with the condition.
Mar 06, 2026
The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.
Mar 06, 2026
Children with obstructive sleep apnea face nearly twice the risk of contracting influenza or COVID-19 compared to controls, with increased vulnerability persisting even after adenotonsillectomy, according to a five-year study of over 1 million children.
Mar 06, 2026
The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.
Mar 04, 2026
Moderna has settled with Arbutus and Genevant, facing a potential $1.3 billion liability contingent on Federal Circuit's decision. Multiple institutional investors have increased their stakes in the biotech company during recent quarters.
Mar 04, 2026
The global mRNA and next-generation vaccine platforms market is expected to grow from $39.69 billion in 2025 to $82.61 billion by 2030 at a 15.8% CAGR, driven by personalized medicine demand and infectious disease applications, while safety concerns and regulatory scrutiny continue.
Mar 03, 2026
Sanofi's oral BTK inhibitor rilzabrutinib received orphan drug designation in Japan for IgG4-related disease and warm autoimmune hemolytic anemia, while also securing U.S. FDA breakthrough therapy designation for the rare anemia indication.
Mar 03, 2026
New research shows 73% of AI users in clinical trials report the technology met or exceeded expectations, with 70% confirming improvements in data accuracy and 93% of organizations already using or investigating AI applications.
Mar 03, 2026
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for Moderna's mCOMBRIAX, the world's first combination Covid-19 and influenza vaccine, for individuals 50 years and older.
Mar 02, 2026
Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation to Sanofi's rilzabrutinib for IgG4-related disease, marking the third global orphan designation for this indication based on positive phase 2 study data.
